{
    "id": 28910,
    "fullName": "UBE2R2 - NTRK3",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "UBE2R2-NTRK3 results from the fusion of UBE2R2 and NTRK3, resulting in cytokine-independent cell growth in culture and increased downstream signaling in vitro (PMID: 29920189). UBE2R2-NTRK3 has been identified in multiple myeloma (PMID: 29920189).",
            "references": [
                {
                    "id": 12810,
                    "pubMedId": 29920189,
                    "title": "Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29920189"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 54926,
        "geneSymbol": "UBE2R2",
        "terms": [
            "UBE2R2",
            "CDC34B",
            "E2-CDC34B",
            "UBC3B"
        ]
    },
    "variant": "UBE2R2 - NTRK3",
    "createDate": "11/13/2018",
    "updateDate": "04/25/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4916,
                "geneSymbol": "NTRK3",
                "terms": [
                    "NTRK3",
                    "gp145(trkC)",
                    "GP145-TrkC",
                    "TRKC"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15198,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing UBE2R2-NTRK3 were sensitive to treatment with Vitrakvi (larotrectinib) in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 29920189).",
            "molecularProfile": {
                "id": 30823,
                "profileName": "UBE2R2 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12810,
                    "pubMedId": 29920189,
                    "title": "Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29920189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30823,
            "profileName": "UBE2R2 - NTRK3",
            "profileTreatmentApproaches": [
                {
                    "id": 19351,
                    "name": "Larotrectinib",
                    "profileName": "UBE2R2 - NTRK3"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}